Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. Summary
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
294.3 296.18 297.67 294.65 295.86 Last
737583 570211 543452 882794 1071329 Volume
-1.10% +0.64% +0.50% -1.01% +0.41% Change
Estimated financial data (e) (USD)
Sales 2022 10 617 M - -
Net income 2022 2 247 M - -
Net Debt 2022 4 023 M - -
P/E ratio 2022 44,8x
Yield 2022 0,99%
Sales 2023 11 627 M - -
Net income 2023 2 658 M - -
Net Debt 2023 3 723 M - -
P/E ratio 2023 37,8x
Yield 2023 1,14%
Capitalization 101 B 101 B -
EV / Sales 2022 9,86x
EV / Sales 2023 8,97x
Nbr of Employees 25 000
Free-Float 99,9%
More Financials
Company
CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two... 
Sector
Pharmaceuticals
Calendar
02/16Earnings Release
More about the company
Ratings of CSL Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about CSL LIMITED
10/19CSL : Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and N..
AQ
10/18CSL Limited Announces New Strategic Collaboration with Walter and Eliza Hall Institute ..
CI
10/18CSL Limited Highlights Progress from Its Novel Pipeline That Spans Six Therapeutic Area..
CI
10/17Miners, energy stocks help Australian shares inch higher
RE
10/15CSL : Reaffirms Commitment to Manufacture 50 Million Doses of AstraZeneca Vaccine
MT
10/14CSL : The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based ..
AQ
10/13Miners, tech stocks lift Australia shares; South32 soars
RE
10/13Australia's CSL reaffirms commitment to making AstraZeneca COVID vaccine
RE
10/13Australia's CSL reiterates manufacturing commitment with AstraZeneca COVID-19 vaccine
RE
10/11CSL Limited Provides Earnings Guidance for Fiscal Year 2022
CI
10/06Banks and healthcare stocks lift Australian shares
RE
10/05Australia shares nearly flat as financials' losses offset tech, healthcare gains
RE
10/05CSL : Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines
AQ
10/05CSL : Launches Annual Scholarship Program with Seven Greater Chicago Area Students Receivi..
AQ
10/04Seqirus, Part of CSL Limited Awarded U.S. Government Contract to Develop Two Pandemic I..
CI
More news
News in other languages on CSL LIMITED
10/15CSL réaffirme son engagement à fabriquer 50 millions de doses du vaccin d'AstraZeneca
08/13FOCUS-Pfizer e Moderna raccoglieranno miliardi di dollari da richiami vaccini Covid
05/05MÄRKTE ASIEN/Schwache US-Vorgaben dämpfen Kauflaune
04/09Australia duplica el pedido de vacunas de Pfizer tras el revés de AstraZeneca
04/07SCOTT MORRISON : L'Australie appelle l'UE à livrer des vaccins, si blocage il n'y a pas
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | MarketScreener
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 220,83 $
Average target price 230,03 $
Spread / Average Target 4,16%
EPS Revisions
Managers and Directors
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors